Wagner Paul A. 4

What Happened

• Paul A. Wagner — listed as Director and noted as CEO, Secretary and Chair of Forte Biosciences (FBRX) — had restricted stock units (RSUs) convert into common shares on April 1, 2026. The filing shows two conversions of 1,250 RSUs each (total 2,500 shares). To satisfy tax withholding, 98 shares were surrendered at $24.86 each, totaling $2,436. Net new shares received by Wagner = 2,402 (2,500 − 98). The RSU conversions carried no exercise price.

Key Details

• Transaction date: 2026-04-01; Form 4 filed: 2026-04-03 (filed timely).
• Conversion entries: two "M" codes (exercise/conversion of derivative) for 1,250 shares each (aggregate 2,500).
• Tax withholding: "F" code — 98 shares surrendered at $24.86/share for $2,436.
• Shares owned after transaction: Not disclosed in the Form 4.
• Footnotes: Each RSU represents a contingent right to one common share. Vesting is subject to continued service and occurs quarterly per the issuer’s 2021 Equity Incentive Plan (1/16th on each Quarterly Vesting Date as defined).

Context

• This was RSU vesting/conversion (an award becoming stock), not an open-market purchase or a deliberate sale. The only disposition was the routine share withholding to cover taxes.
• For retail investors: awards/vests increase insider ownership but do not directly signal buying conviction like open-market purchases. This filing appears routine and was reported within the normal Form 4 window.